Monday, November 27, 2023 8:18:51 AM
meirluc : is there a complete list of all the errors in the Reardon paper ?
Re: flipper44 post# 650509
Saturday, November 25, 2023 6:00:57 PM
Post#
650576
of 650906
Ethan Chen's et al. second monumental error was embedded in the following
sentence of their review.
"The mOS for the Placebo group was not reported because 90% of subjects
crossed over from the placebo to the DCVax-L group upon determination of
progression (based on MRI) from treatment."
If I understand it correctly, Chen et al. were implying that of the 99 placebos, 90%
(about 89 patients) received DCVax-L after their progression when in fact only
64 of those original 99 placebos received the vaccine after progression. Instead, it was
90% of all 331 trial patients (296 patients) who received DCVax-L, with 232 treatment
patients receiving the vaccine before their progression and 64 receiving the vaccine after
progression.
Is there now any reason why the Ethan Chen group's review should not be withdrawn?
Bullish
BULLISH
Re: flipper44 post# 650509
Saturday, November 25, 2023 6:00:57 PM
Post#
650576
of 650906
Ethan Chen's et al. second monumental error was embedded in the following
sentence of their review.
"The mOS for the Placebo group was not reported because 90% of subjects
crossed over from the placebo to the DCVax-L group upon determination of
progression (based on MRI) from treatment."
If I understand it correctly, Chen et al. were implying that of the 99 placebos, 90%
(about 89 patients) received DCVax-L after their progression when in fact only
64 of those original 99 placebos received the vaccine after progression. Instead, it was
90% of all 331 trial patients (296 patients) who received DCVax-L, with 232 treatment
patients receiving the vaccine before their progression and 64 receiving the vaccine after
progression.
Is there now any reason why the Ethan Chen group's review should not be withdrawn?
Bullish
BULLISH
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
